Company Analysis Mirati Therapeutics, Inc.
1. Summary
Advantages
- Price (58.7 $) is less than fair price (68.22 $)
- The stock's return over the last year (-0.3396%) is higher than the sector average (-15.96%).
Disadvantages
- Dividends (0%) are below the sector average (0.5442%).
- Current debt level 4.28% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-61.91%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Mirati Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -16.8% | 0.4% |
| 90 days | 0% | -20.8% | 6.1% |
| 1 year | -0.3% | -16% | 31.5% |
MRTX vs Sector: Mirati Therapeutics, Inc. has outperformed the "Healthcare" sector by 15.62% over the past year.
MRTX vs Market: Mirati Therapeutics, Inc. has significantly underperformed the market by -31.8% over the past year.
Stable price: MRTX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MRTX with weekly volatility of -0.0065% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (58.7 $) is lower than the fair price (68.22 $).
Price not significantly lower than the fair price: The current price (58.7 $) is slightly lower than the fair price by 16.2%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.79).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.4) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (2.4) is lower than that of the market as a whole (3.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (192.63) is higher than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (192.63) is higher than that of the market as a whole (10.23).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.91) is higher than that of the sector as a whole (-22.15).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.91) is lower than that of the market as a whole (28.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 21.39% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (21.39%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (-61.91%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-61.91%) is lower than that of the market as a whole (10.82%).
5.5. ROA
ROA vs Sector: The company's ROA (-53.08%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-53.08%) is lower than that of the market as a whole (6.51%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-48.9%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-48.9%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5442%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 02.06.2023 | Stelzer Laurie Chief Financial Officer |
Sale | 37.06 | 172 218 | 4 647 |
| 28.11.2022 | BAUM CHARLES M President,Founder,Head of R&D |
Sale | 100 | 6 925 600 | 69 256 |
| 28.11.2022 | BAUM CHARLES M President,Founder,Head of R&D |
Purchase | 17.41 | 1 205 750 | 69 256 |
| 07.01.2022 | REED VICKIE S SVP, Chief Accounting Officer |
Sale | 135.94 | 46 899 | 345 |
| 07.01.2022 | Hickey Benjamin EVP, Chief Commercial Officer |
Sale | 135.94 | 266 986 | 1 964 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
